Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Directly Observed Fluoxetine for Depression in Hemodialysis
NCT03390933Phase 4Completed
- Sponsor
- MetroHealth Medical Center
- Start
- Mar 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluoxetine in major depressive disorder (MDD), sponsored by MetroHealth Medical Center. Primary endpoint: Remission of Depression at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03390933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03390933.